Seegene's Revolutionary Unattended PCR System Set to Transform Global Diagnostics Landscape

Seegene Unveils a New Era in Diagnostics with CURECA™ and STAgora™

At the upcoming ADLM (Association for Diagnostics and Laboratory Medicine) 2025 conference in Chicago, running from July 28 to 31, Seegene Inc., a leader in molecular diagnostics, will unveil its pioneering unattended PCR testing system, CURECA™, along with its data analysis platform, STAgora™. This reveal marks a significant shift in the diagnostic landscape, promising enhanced efficiency and precision without human intervention.

CURECA™: The Future of Automated Testing

CURECA™ is heralded as the first fully automated PCR testing system that streamlines the entire testing process—from sample storage and pretreatment to nucleic acid extraction, amplification, and result analysis—without any human input. Operating around the clock, this innovative system minimizes human error, thereby improving the consistency and reliability of test results.

One of the key breakthroughs of CURECA™ is its fully automated preparatory module. Traditionally, the preparatory step has been one of the most labor-intensive and error-prone phases in the laboratory process. Laboratory technicians often deal with various sample types, including urine, blood, sputum, and feces, requiring repetitive manual tasks over long hours. Differences in skill levels among technicians can also lead to inconsistent results, particularly for challenging samples such as stool, which add complexity due to viscosity and particulate matter.

The CURECA™ preparatory module addresses these challenges by fully automating the pretreatment process across all primary sample types, including stool. This automation not only reduces labor demands but also enhances sample throughput and overall operational and cost efficiency. It redefines the role of laboratory personnel from manual processing to more responsible tasks such as data analysis and clinical interpretation. As hospitals operate in high-volume environments 24/7, this technological advancement ensures consistently high-quality testing results.

Furthermore, the preparatory module extends its utility beyond PCR diagnostics. It can facilitate pretreatment for other fields, including clinical chemistry and immunological testing, representing a significant leap in automation across the diagnostic marketplace. Its modular architecture allows for flexible configuration and deployment tailored to each laboratory's size, layout, and specific needs.

STAgora™: Real-Time Global Data Integration for Personalized Care

At ADLM 2025, Seegene will also introduce STAgora™, its statistical platform designed to collect and analyze real-time diagnostic data from PCR tests, thus supporting clinical decision-making. By aggregating test data from hospitals worldwide, STAgora™ provides an integrated view of regional infection trends, hospital-level positivity rates, and co-infection patterns, complete with over 40 statistical tools for clinical support.

This platform empowers healthcare providers to compare individual patient test results against local and regional epidemiological data, enabling data-driven treatment strategies. It allows clinicians to assess infection trends at both patient and community levels, thereby enhancing diagnostic accuracy and care planning speed. Expectations are high that STAgora™ will become an essential analytical tool for clinical decision-making by delivering timely and reliable information.

Expanding Global Cooperation through Technology Sharing

As part of its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ through early pilot experiences and the establishment of new global partnerships. Earlier this year, CURECA™ generated significant interest at the ESCMID Global 2025, a leading European congress focused on clinical microbiology and infectious diseases. To reinforce its capabilities in research, development, and manufacturing in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

Daniel Shin, Seegene's Executive Vice President and Global Sales and Marketing Director, stated, "CURECA™ and STAgora™ are more than just diagnostic devices or software—they represent a new global standard that redefines diagnostics in clinical settings worldwide. We will continue to share many of the technological assets we have built over the years, and based on this, we commit to driving fundamental innovations in the global diagnostic ecosystem."

As Seegene prepares for this transformative launch, it reaffirms its leadership in the field of molecular diagnostics, a reputation bolstered over more than two decades of expertise and significant contributions during the COVID-19 pandemic, including the distribution of over 340 million COVID-19 tests to more than 100 countries. To learn more about Seegene, visit Seegene.com or follow them on LinkedIn at Seegene Inc..